Bernard A. Fox: Guidelines for Optimizing NBTXR3 Nanoparticle Injection in Head and Neck Cancer: A Collaborative Achievement
Bernard A. Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn:
“Wonderful to start the week with a joint lab meeting between Prof. Rieneke van de Ven’s team in the Laboratory of Head and neck cancer biology and immunology, and the FoxLab at the Earle A. Chiles Research Institute within the Providence Cancer Institute.
Delighted that Prof. Ruud H Brakenhoff, Chair of the group at the Amsterdam UMC also joined in. Dennis Nijenhuis, a PhD student from Dr. van de Ven’s lab at the VU who is spending 6 months in my lab.
Today, he presented work evaluating tertiary lymphoid follicles in head and neck cancer. Dennis has already made great progress and we are looking forward to him wrapping up this work, as well as his seromic studies, by the end of May. Another wonderful International effort to Finish Cancer! Apologies to the members of both teams that weren’t captured in the photo.”
Source: Bernard A. Fox/LinkedIn